$NBIX
NEUROCRINE BIOSCIENCES INC

2014 Q4 Form 10-Q Financial Statement

#000119312514395717 Filed on November 04, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q3
Revenue $0.00 $0.00 $729.0K
YoY Change -100.0% -100.0% -92.21%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.000M $4.700M $3.200M
YoY Change 51.52% 46.88% -3.03%
% of Gross Profit
Research & Development $15.50M $12.19M $9.490M
YoY Change 74.16% 28.49% -3.75%
% of Gross Profit
Depreciation & Amortization $200.0K $200.0K $200.0K
YoY Change 0.0% 0.0% 0.0%
% of Gross Profit
Operating Expenses $20.47M $16.86M $12.74M
YoY Change 66.95% 32.37% -4.38%
Operating Profit -$16.86M -$12.01M
YoY Change 40.4% 203.03%
Interest Expense $200.0K $200.0K $100.0K
YoY Change 100.0% 100.0% 0.0%
% of Operating Profit
Other Income/Expense, Net $800.0K $982.0K $875.0K
YoY Change 0.0% 12.23% -1.02%
Pretax Income -$19.40M -$15.90M -$11.10M
YoY Change 83.02% 43.24% 258.06%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$19.44M -$15.88M -$11.13M
YoY Change 82.71% 42.62% 261.63%
Net Earnings / Revenue -1526.89%
Basic Earnings Per Share -$0.17
Diluted Earnings Per Share -$254.6K -$209.5K -$0.17
COMMON SHARES
Basic Shares Outstanding 76.01M shares 75.92M shares 67.20M shares
Diluted Shares Outstanding 67.20M shares

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $193.8M $179.7M $156.9M
YoY Change 33.01% 14.53% -9.83%
Cash & Equivalents $31.01M $29.05M $34.89M
Short-Term Investments $162.8M $150.6M $122.0M
Other Short-Term Assets $4.394M $4.194M $2.232M
YoY Change 61.37% 87.9% -16.96%
Inventory
Prepaid Expenses
Receivables $100.0K
Other Receivables $0.00
Total Short-Term Assets $198.2M $183.9M $159.2M
YoY Change 33.5% 15.48% -10.56%
LONG-TERM ASSETS
Property, Plant & Equipment $2.507M $2.292M $1.739M
YoY Change 41.56% 31.8% -14.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $37.50M $67.10M $700.0K
YoY Change 9485.71% -92.13%
Other Assets $4.800M $4.400M $4.300M
YoY Change 9.09% 2.33% 0.0%
Total Long-Term Assets $44.83M $73.88M $6.749M
YoY Change 621.44% 994.73% -55.69%
TOTAL ASSETS
Total Short-Term Assets $198.2M $183.9M $159.2M
Total Long-Term Assets $44.83M $73.88M $6.749M
Total Assets $243.0M $257.8M $166.0M
YoY Change 57.12% 55.3% -14.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $246.0K $900.0K $1.097M
YoY Change 143.56% -17.96% -22.53%
Accrued Expenses $11.51M $9.307M $7.882M
YoY Change 44.66% 18.08% -3.05%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.66M $14.05M $13.32M
YoY Change 33.89% 5.44% -42.37%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $260.0K $260.0K $152.0K
YoY Change 0.0% 71.05% 0.0%
Total Long-Term Liabilities $260.0K $260.0K $152.0K
YoY Change 0.0% 71.05% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.66M $14.05M $13.32M
Total Long-Term Liabilities $260.0K $260.0K $152.0K
Total Liabilities $34.33M $33.71M $36.68M
YoY Change 0.2% -8.07% -26.57%
SHAREHOLDERS EQUITY
Retained Earnings -$826.3M -$806.9M -$755.1M
YoY Change 7.91% 6.85% 3.56%
Common Stock $1.035B $76.00K $67.00K
YoY Change 1545095.52% 13.43% 1.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $208.7M $224.0M $129.3M
YoY Change
Total Liabilities & Shareholders Equity $243.0M $257.8M $166.0M
YoY Change 57.12% 55.3% -14.12%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income -$19.44M -$15.88M -$11.13M
YoY Change 82.71% 42.62% 261.63%
Depreciation, Depletion And Amortization $200.0K $200.0K $200.0K
YoY Change 0.0% 0.0% 0.0%
Cash From Operating Activities -$15.30M -$12.10M -$10.80M
YoY Change 40.37% 12.04% 30.12%
INVESTING ACTIVITIES
Capital Expenditures -$400.0K -$300.0K -$100.0K
YoY Change 300.0% 200.0% -66.67%
Acquisitions
YoY Change
Other Investing Activities $15.90M $3.500M -$1.200M
YoY Change -23.92% -391.67% -110.91%
Cash From Investing Activities $15.50M $3.200M -$1.300M
YoY Change -25.12% -346.15% -112.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.700M 500.0K 2.700M
YoY Change -81.48% 2600.0%
NET CHANGE
Cash From Operating Activities -15.30M -12.10M -10.80M
Cash From Investing Activities 15.50M 3.200M -1.300M
Cash From Financing Activities 1.700M 500.0K 2.700M
Net Change In Cash 1.900M -8.400M -9.400M
YoY Change -80.61% -10.64% -476.0%
FREE CASH FLOW
Cash From Operating Activities -$15.30M -$12.10M -$10.80M
Capital Expenditures -$400.0K -$300.0K -$100.0K
Free Cash Flow -$14.90M -$11.80M -$10.70M
YoY Change 37.96% 10.28% 33.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q2 nbix Cease Use Liability
CeaseUseLiability
3295000
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34889000
CY2013Q3 nbix Cease Use Liability
CeaseUseLiability
3198000
CY2014Q2 nbix Cease Use Liability
CeaseUseLiability
2892000
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75996384 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
75996384 shares
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
110000000 shares
CY2014Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
85000
CY2014Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14045000
CY2014Q3 us-gaap Sale Leaseback Transaction Deferred Gain Net
SaleLeasebackTransactionDeferredGainNet
18500000
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
76000
CY2014Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1916000
CY2014Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
21000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29046000
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2292000
CY2014Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
217776000
CY2014Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
164365000
CY2014Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4443000
CY2014Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
228000
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-207000
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
900000
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-806861000
CY2014Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9307000
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
224037000
CY2014Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
260000
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
257751000
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1031029000
CY2014Q3 us-gaap Liabilities
Liabilities
33714000
CY2014Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0
CY2014Q3 us-gaap Long Term Investments
LongTermInvestments
67148000
CY2014Q3 us-gaap Assets
Assets
257751000
CY2014Q3 us-gaap Short Term Investments
ShortTermInvestments
150628000
CY2014Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
228000
CY2014Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
228000
CY2014Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
217983000
CY2014Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2014Q3 us-gaap Other Assets Current
OtherAssetsCurrent
4194000
CY2014Q3 us-gaap Assets Current
AssetsCurrent
183868000
CY2014Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
164365000
CY2014Q3 us-gaap Investments
Investments
217800000
CY2014Q3 nbix Letters Of Credit Collateral
LettersOfCreditCollateral
4200000
CY2014Q3 nbix Number Of Renewal Options
NumberOfRenewalOptions
2 RenewalOptions
CY2014Q3 nbix Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
3299000
CY2014Q3 nbix Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
2334000
CY2014Q3 nbix Cease Use Liability Current
CeaseUseLiabilityCurrent
454000
CY2014Q3 nbix Cease Use Liability
CeaseUseLiability
2788000
CY2014Q3 nbix Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
15159000
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
76005155 shares
CY2008Q4 us-gaap Sale Leaseback Transaction Deferred Gain Net
SaleLeasebackTransactionDeferredGainNet
39100000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63754000
CY2012Q4 nbix Cease Use Liability
CeaseUseLiability
3686000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
67351195 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
67351195 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
110000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
0
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11699000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
67000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
101000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-765763000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7955000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
120410000
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
260000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
154676000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
886101000
CY2013Q4 us-gaap Liabilities
Liabilities
34266000
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1982000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44789000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1771000
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
100950000
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
39721000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4443000
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0
CY2013Q4 us-gaap Long Term Investments
LongTermInvestments
0
CY2013Q4 us-gaap Assets
Assets
154676000
CY2013Q4 us-gaap Short Term Investments
ShortTermInvestments
100950000
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
15000
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
15000
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2723000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
148462000
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
39721000
CY2013Q4 us-gaap Investments
Investments
101000000
CY2013Q4 nbix Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
3227000
CY2013Q4 nbix Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
2680000
CY2013Q4 nbix Cease Use Liability Current
CeaseUseLiabilityCurrent
416000
CY2013Q4 nbix Cease Use Liability
CeaseUseLiability
3096000
CY2013Q4 nbix Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
17645000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
800000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2200000 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-18728000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
66868000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
300000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
900000 shares
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
2382000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2108000
us-gaap Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
2300000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
130379000
us-gaap Licenses Revenue
LicensesRevenue
2189000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-13944000
us-gaap Operating Income Loss
OperatingIncomeLoss
-38148000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
38000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35455000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2700000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
us-gaap Revenues
Revenues
2189000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
354000
us-gaap Net Income Loss
NetIncomeLoss
-35448000
us-gaap Investment Income Net
InvestmentIncomeNet
317000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-7000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5100000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2189000
us-gaap Operating Expenses
OperatingExpenses
40337000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30330000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
115000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-28865000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
515000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5252000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5252000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
38000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-15389000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5300000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
115306000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10007000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-26000
us-gaap Share Based Compensation
ShareBasedCompensation
5123000
nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
2344000
nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-488000
nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
488000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
900000 shares
dei Document Type
DocumentType
10-Q
dei Entity Registrant Name
EntityRegistrantName
NEUROCRINE BIOSCIENCES INC
dei Trading Symbol
TradingSymbol
NBIX
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2800000 shares
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-31831000
us-gaap Property Management Fee Percent Fee
PropertyManagementFeePercentFee
0.035 pure
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> <i>Use of Estimates</i>. The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</p> </div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
74050000 shares
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
2410000
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30927000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
19000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
603000
us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
93000 shares
dei Entity Central Index Key
EntityCentralIndexKey
0000914475
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.56
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
900000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
600000 shares
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2745000
us-gaap Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
2400000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
241156000
us-gaap Licenses Revenue
LicensesRevenue
0
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
1471000
us-gaap Operating Income Loss
OperatingIncomeLoss
-43943000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-4000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41310000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2845000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000
us-gaap Revenues
Revenues
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1173000
us-gaap Net Income Loss
NetIncomeLoss
-41098000
us-gaap Investment Income Net
InvestmentIncomeNet
432000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-212000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7900000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
us-gaap Operating Expenses
OperatingExpenses
43943000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-15743000
CY2007Q4 us-gaap Mortgage Loans On Real Estate Cost Of Mortgages Sold
MortgageLoansOnRealEstateCostOfMortgagesSold
47700000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
136999000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
136999000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
45000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-120911000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3800000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
121373000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13016000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2151000
us-gaap Share Based Compensation
ShareBasedCompensation
7938000
nbix Lease Expiration Year
LeaseExpirationYear
2019
nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
2414000
nbix Lease Extension Period
LeaseExtensionPeriod
P10Y
nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-308000
nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
308000
CY2014Q1 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
17.75
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
8000000 shares
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
133200000
CY2007Q4 us-gaap Sale Leaseback Transaction Net Proceeds Financing Activities
SaleLeasebackTransactionNetProceedsFinancingActivities
61000000
CY2007Q4 us-gaap Sale Leaseback Transaction Gross Proceeds Investing Activities
SaleLeasebackTransactionGrossProceedsInvestingActivities
109000000
CY2007Q4 nbix Number Of Buildings Leased
NumberOfBuildingsLeased
2 Building
CY2007Q4 nbix Sale Leaseback Transaction Lease Period
SaleLeasebackTransactionLeasePeriod
P12Y
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
CY2013Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2500000 shares
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
67199000 shares
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
100000 shares
CY2013Q3 us-gaap Licenses Revenue
LicensesRevenue
729000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12006000
CY2013Q3 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
6000
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11096000
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
875000
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
CY2013Q3 us-gaap Revenues
Revenues
729000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-11131000
CY2013Q3 us-gaap Investment Income Net
InvestmentIncomeNet
93000
CY2013Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
35000
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1700000
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
12735000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
16857000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12194000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4663000
CY2014Q3 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
805000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9490000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3245000
CY2013Q3 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
781000
CY2013Q3 nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
97000
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
CY2014Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2800000 shares
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
75948000 shares
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
900000 shares
CY2014Q3 us-gaap Licenses Revenue
LicensesRevenue
0
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-16857000
CY2014Q3 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
1000
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15956000
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
982000
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2014Q3 us-gaap Revenues
Revenues
0
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-15875000
CY2014Q3 us-gaap Investment Income Net
InvestmentIncomeNet
176000
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-81000
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2700000
CY2014Q3 nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
104000

Files In Submission

Name View Source Status
0001193125-14-395717-index-headers.html Edgar Link pending
0001193125-14-395717-index.html Edgar Link pending
0001193125-14-395717.txt Edgar Link pending
0001193125-14-395717-xbrl.zip Edgar Link pending
d786994d10q.htm Edgar Link pending
d786994dex101.htm Edgar Link pending
d786994dex311.htm Edgar Link pending
d786994dex312.htm Edgar Link pending
d786994dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
nbix-20140930.xml Edgar Link completed
nbix-20140930.xsd Edgar Link pending
nbix-20140930_cal.xml Edgar Link unprocessable
nbix-20140930_def.xml Edgar Link unprocessable
nbix-20140930_lab.xml Edgar Link unprocessable
nbix-20140930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending